瑞银发表报告，列出最具潜力超市场预期收益((Buy rated HK listed stocks with highest UBSe earnings upside above consensus estimate)的港股买入名单：股份│瑞银与同业对企业今明两年综合盈测差异康希诺生物(06185.HK) +0.040 (+0.115%) 沽空 $42.59万; 比率 6.864% │97%石药集团(01093.HK) +0.050 (+0.593%) 沽空 $9.76千万; 比率 29.902% │60%三生制药(01530.HK) +0.400 (+1.654%) 沽空 $1.36千万; 比率 8.508% │42%科济药业-B(02171.HK) +0.470 (+3.165%) 沽空 $2.17百万; 比率 15.951% │42%上石化(00338.HK) +0.010 (+0.730%) 沽空 $42.74万; 比率 15.840% │37%越秀地产(00123.HK) +0.060 (+1.515%) 沽空 $3.05百万; 比率 22.111% │35%金风科技(02208.HK) +2.810 (+20.955%) 沽空 $4.63千万; 比率 11.802% │33%科伦博泰生物-B(06990.HK) +8.400 (+2.142%) 沽空 $1.66千万; 比率 55.377% │27%中信建投证券(06066.HK) +0.290 (+2.259%) 沽空 $4.94百万; 比率 19.461% │26%恒瑞医药(01276.HK) +2.850 (+4.000%) 沽空 $1.81千万; 比率 14.562% │25%海丰国际(01308.HK) +0.280 (+1.005%) 沽空 $1.39千万; 比率 13.827% │23%药明康德(02359.HK) +2.300 (+2.330%) 沽空 $1.05千万; 比率 9.982% │22%(wl/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-01-02 16:25。)